Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) CEO James Richard Porter sold 27,000 shares of Nuvalent stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $102.28, for a total transaction of $2,761,560.00. Following the completion of the transaction, the chief executive officer now owns 188,113 shares in the company, valued at approximately $19,240,197.64. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Nuvalent Stock Down 2.5 %
Nuvalent stock opened at $102.16 on Friday. The firm's 50-day simple moving average is $91.74 and its 200 day simple moving average is $79.40. Nuvalent, Inc. has a 52 week low of $49.02 and a 52 week high of $113.51. The firm has a market capitalization of $6.60 billion, a PE ratio of -42.39 and a beta of 1.29.
Nuvalent (NASDAQ:NUVL - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). During the same quarter in the previous year, the business earned ($0.51) EPS. On average, research analysts expect that Nuvalent, Inc. will post -3.52 EPS for the current fiscal year.
Institutional Inflows and Outflows
Tim Sykes’ Urgent Trade Alert: “Make this move now”
From Timothy Sykes | Ad
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock
This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…
Click here to see a unique election-year trade
Institutional investors have recently added to or reduced their stakes in the company. Quest Partners LLC acquired a new position in Nuvalent in the 2nd quarter valued at about $44,000. Amalgamated Bank raised its stake in Nuvalent by 21.8% in the 2nd quarter. Amalgamated Bank now owns 1,105 shares of the company's stock valued at $84,000 after purchasing an additional 198 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of Nuvalent during the 1st quarter valued at about $121,000. Allspring Global Investments Holdings LLC increased its stake in shares of Nuvalent by 9.2% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,235 shares of the company's stock valued at $168,000 after acquiring an additional 189 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC acquired a new position in shares of Nuvalent during the 1st quarter valued at about $202,000. Institutional investors and hedge funds own 97.26% of the company's stock.
Analyst Ratings Changes
Several brokerages have commented on NUVL. Wedbush boosted their target price on shares of Nuvalent from $99.00 to $115.00 and gave the stock an "outperform" rating in a research report on Monday, September 16th. Guggenheim boosted their target price on shares of Nuvalent from $99.00 to $105.00 and gave the stock a "buy" rating in a research report on Monday, September 16th. JPMorgan Chase & Co. boosted their target price on shares of Nuvalent from $100.00 to $125.00 and gave the stock an "overweight" rating in a research report on Friday, October 4th. Stifel Nicolaus boosted their target price on shares of Nuvalent from $115.00 to $135.00 and gave the stock a "buy" rating in a research report on Monday, September 16th. Finally, BMO Capital Markets boosted their target price on shares of Nuvalent from $102.00 to $132.00 and gave the stock an "outperform" rating in a research report on Monday, September 16th. One research analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Nuvalent presently has an average rating of "Moderate Buy" and an average target price of $113.78.
View Our Latest Report on NUVL
Nuvalent Company Profile
(
Get Free Report)
Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
